JP2023089103A5 - - Google Patents

Download PDF

Info

Publication number
JP2023089103A5
JP2023089103A5 JP2023063975A JP2023063975A JP2023089103A5 JP 2023089103 A5 JP2023089103 A5 JP 2023089103A5 JP 2023063975 A JP2023063975 A JP 2023063975A JP 2023063975 A JP2023063975 A JP 2023063975A JP 2023089103 A5 JP2023089103 A5 JP 2023089103A5
Authority
JP
Japan
Prior art keywords
polypeptide
vector
collection
pharmaceutical composition
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023063975A
Other languages
English (en)
Japanese (ja)
Other versions
JP7485422B2 (ja
JP2023089103A (ja
Filing date
Publication date
Priority claimed from JP2020524616A external-priority patent/JP7386537B2/ja
Application filed filed Critical
Publication of JP2023089103A publication Critical patent/JP2023089103A/ja
Publication of JP2023089103A5 publication Critical patent/JP2023089103A5/ja
Application granted granted Critical
Publication of JP7485422B2 publication Critical patent/JP7485422B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023063975A 2017-11-03 2023-04-11 ワクチンt細胞エンハンサー Active JP7485422B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP17200036 2017-11-03
EP17200036.6 2017-11-03
EP17211235.1 2017-12-29
EP17211235 2017-12-29
JP2020524616A JP7386537B2 (ja) 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー
PCT/EP2018/080027 WO2019086615A1 (en) 2017-11-03 2018-11-02 Vaccine t cell enhancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020524616A Division JP7386537B2 (ja) 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー

Publications (3)

Publication Number Publication Date
JP2023089103A JP2023089103A (ja) 2023-06-27
JP2023089103A5 true JP2023089103A5 (https=) 2024-03-05
JP7485422B2 JP7485422B2 (ja) 2024-05-16

Family

ID=64332267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020524616A Active JP7386537B2 (ja) 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー
JP2023063975A Active JP7485422B2 (ja) 2017-11-03 2023-04-11 ワクチンt細胞エンハンサー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020524616A Active JP7386537B2 (ja) 2017-11-03 2018-11-02 ワクチンt細胞エンハンサー

Country Status (12)

Country Link
US (1) US11912743B2 (https=)
EP (1) EP3703744A1 (https=)
JP (2) JP7386537B2 (https=)
KR (1) KR102747530B1 (https=)
CN (1) CN111670046B (https=)
AU (1) AU2018358019B2 (https=)
BR (1) BR112020008308A2 (https=)
CA (1) CA3078692A1 (https=)
IL (1) IL274409B2 (https=)
MX (1) MX2020004552A (https=)
SG (1) SG11202003799RA (https=)
WO (1) WO2019086615A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210081325A (ko) * 2018-10-19 2021-07-01 노우스콤 아게 경골어류 불변 사슬 암 백신
SG11202103243PA (en) * 2018-11-15 2021-04-29 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
EP4135757A1 (en) * 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4448001A4 (en) * 2021-12-16 2025-12-03 Janssen Biotech Inc PROSTATE CANCER VACCINES AND THEIR USES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
HUE045093T2 (hu) * 2008-11-21 2019-12-30 Kobenhavns Univ University Of Copenhagen Immunválasz kiváltása
EP2391638B1 (en) 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
WO2016013672A1 (ja) 2014-07-25 2016-01-28 国立研究開発法人理化学研究所 メモリーインバリアントnkt細胞マーカー
JP7298926B2 (ja) * 2017-07-12 2023-06-27 ノイスコム アーゲー 癌の治療のためのネオアンチゲンワクチン組成物

Similar Documents

Publication Publication Date Title
JP2023089103A5 (https=)
Gange et al. Kaposi's sarcoma and immunosuppressive therapy: an appraisal
AU723147B2 (en) Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CN105377291B (zh) 免疫原性wt-1肽和其使用方法
CN1131712C (zh) 初乳肽及其用途
JPH06508988A (ja) 乳頭腫ウイルスl2蛋白
ES2365077T3 (es) Péptido antígeno anticáncer derivado de sparc y composición farmacéutica que comprende el mismo.
BR0108566A (pt) Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
KR20200123696A (ko) 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
TW200824705A (en) Reconstituted surfactants having improved properties
CN113880915A (zh) 用于修复黏膜损伤或皮肤创伤的多肽及其应用
JP6293882B2 (ja) 遺伝的に安定な腫瘍溶解性rnaウイルス、その製造方法およびその使用
JP5243624B2 (ja) 抗原ペプチドおよびその利用
GB1604850A (en) Biologically active peptides
ES2876036T3 (es) Composición que contiene una bacteria láctica, composición farmacéutica oral para su uso en el tratamiento de infecciones por VPH y/o tumores asociados a VPH y agente inductor de inmunidad de la mucosa para su uso en dotar de inmunidad mucosal contra la infección por VPH
TW434257B (en) Proteins from mammalian liver and their use in oncology
ES2390967T3 (es) Epítopo/péptido reconocido por LTC específico para Ep-CAM con restricción por ALH-A2402 y su utilización
JPH10501003A (ja) 免疫調節作用を有する新規ペプチド
Kimmelman et al. Small cell carcinomas of the head and neck
CN107805282A (zh) 一种靶向疗法和免疫疗法联合的多肽
KR20220079081A (ko) 결핵의 예방 또는 치료용 약학적 조성물
CN114478712B (zh) Hpv抗原表位及其鉴定方法、应用
JP2001508764A (ja) 免疫原性tlp組成物
Penn Immunosuppression and cancer: importance in head and neck surgery
JP2001511143A (ja) コラーゲン▲ii▼に特異的なt細胞エピトープを含むペプチド